Epidemiology of COVID-19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes
Background. The outbreak of coronavirus disease 2019 (COVID-19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR. Methods. This observational cohort study was performed from 20th March 2020 to 18th March 2021 in three tertiary educational hospitals in Tehran, Iran. All patients were admitted based on the WHO, CDC, and Iran’s National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, clinical profile, outcomes of disease, and finding the predictors of death due to COVID-19. Results. Of all 5318 participants, the median age was 60.0 years, and 57.2% of patients were male. The most significant comorbidities were hypertension and diabetes mellitus. Cough, dyspnea, and fever were the most dominant symptoms. Results showed that ICU admission, elderly age, decreased consciousness, low BMI, HTN, IHD, CVA, dialysis, intubation, Alzheimer disease, blood injection, injection of platelets or FFP, and high number of comorbidities were associated with a higher risk of death related to COVID-19. The trend of CFR was increasing (WPC: 1.86) during weeks 25 to 51. Conclusions. Accurate detection of predictors of poor outcomes helps healthcare providers in stratifying patients, based on their risk factors and healthcare requirements to improve their survival chance..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
---|---|
Enthalten in: |
BioMed Research International - (2022) |
Sprache: |
Englisch |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
---|
doi: |
10.1155/2022/2350063 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ02814998X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ02814998X | ||
003 | DE-627 | ||
005 | 20230307123436.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1155/2022/2350063 |2 doi | |
035 | |a (DE-627)DOAJ02814998X | ||
035 | |a (DE-599)DOAJ81fdcbebef7849f1a3b3141e124039fc | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a Hamidreza Hatamabadi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Epidemiology of COVID-19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background. The outbreak of coronavirus disease 2019 (COVID-19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR. Methods. This observational cohort study was performed from 20th March 2020 to 18th March 2021 in three tertiary educational hospitals in Tehran, Iran. All patients were admitted based on the WHO, CDC, and Iran’s National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, clinical profile, outcomes of disease, and finding the predictors of death due to COVID-19. Results. Of all 5318 participants, the median age was 60.0 years, and 57.2% of patients were male. The most significant comorbidities were hypertension and diabetes mellitus. Cough, dyspnea, and fever were the most dominant symptoms. Results showed that ICU admission, elderly age, decreased consciousness, low BMI, HTN, IHD, CVA, dialysis, intubation, Alzheimer disease, blood injection, injection of platelets or FFP, and high number of comorbidities were associated with a higher risk of death related to COVID-19. The trend of CFR was increasing (WPC: 1.86) during weeks 25 to 51. Conclusions. Accurate detection of predictors of poor outcomes helps healthcare providers in stratifying patients, based on their risk factors and healthcare requirements to improve their survival chance. | ||
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
700 | 0 | |a Tahereh Sabaghian |e verfasserin |4 aut | |
700 | 0 | |a Amir Sadeghi |e verfasserin |4 aut | |
700 | 0 | |a Kamran Heidari |e verfasserin |4 aut | |
700 | 0 | |a Seyed Amir Ahmad Safavi-Naini |e verfasserin |4 aut | |
700 | 0 | |a Mehdi Azizmohammad Looha |e verfasserin |4 aut | |
700 | 0 | |a Nazanin Taraghikhah |e verfasserin |4 aut | |
700 | 0 | |a Shayesteh Khalili |e verfasserin |4 aut | |
700 | 0 | |a Keivan Karrabi |e verfasserin |4 aut | |
700 | 0 | |a Afsaneh Saffarian |e verfasserin |4 aut | |
700 | 0 | |a Saba Shahsavan |e verfasserin |4 aut | |
700 | 0 | |a Hossein Majlesi |e verfasserin |4 aut | |
700 | 0 | |a Amirreza Allahgholipour Komleh |e verfasserin |4 aut | |
700 | 0 | |a Saba Hatari |e verfasserin |4 aut | |
700 | 0 | |a Nadia Zameni |e verfasserin |4 aut | |
700 | 0 | |a Saba Ilkhani |e verfasserin |4 aut | |
700 | 0 | |a Shideh Moftakhari Hajimirzaei |e verfasserin |4 aut | |
700 | 0 | |a Aydin Ghaffari |e verfasserin |4 aut | |
700 | 0 | |a Mohammad Mahdi Fallah |e verfasserin |4 aut | |
700 | 0 | |a Reyhaneh Kalantar |e verfasserin |4 aut | |
700 | 0 | |a Nariman Naderi |e verfasserin |4 aut | |
700 | 0 | |a Parnian Bahmaei |e verfasserin |4 aut | |
700 | 0 | |a Naghmeh Asadimanesh |e verfasserin |4 aut | |
700 | 0 | |a Romina Esbati |e verfasserin |4 aut | |
700 | 0 | |a Omid Yazdani |e verfasserin |4 aut | |
700 | 0 | |a Fatemeh Shojaeian |e verfasserin |4 aut | |
700 | 0 | |a Zahra Azizan |e verfasserin |4 aut | |
700 | 0 | |a Nastaran Ebrahimi |e verfasserin |4 aut | |
700 | 0 | |a Fateme Jafarzade |e verfasserin |4 aut | |
700 | 0 | |a Amirali Soheili |e verfasserin |4 aut | |
700 | 0 | |a Fatemeh Gholampoor |e verfasserin |4 aut | |
700 | 0 | |a Negarsadat Namazi |e verfasserin |4 aut | |
700 | 0 | |a Ali Solhpour |e verfasserin |4 aut | |
700 | 0 | |a Tannaz Jamialahamdi |e verfasserin |4 aut | |
700 | 0 | |a Mohamad Amin Pourhoseingholi |e verfasserin |4 aut | |
700 | 0 | |a Amirhossein Sahebkar |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t BioMed Research International |d Hindawi Limited, 2013 |g (2022) |w (DE-627)DOAJ000078204 |x 23146141 |7 nnns |
773 | 1 | 8 | |g year:2022 |
856 | 4 | 0 | |u https://doi.org/10.1155/2022/2350063 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/81fdcbebef7849f1a3b3141e124039fc |z kostenfrei |
856 | 4 | 0 | |u http://dx.doi.org/10.1155/2022/2350063 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2314-6141 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |j 2022 |